You are here

Safety and Tolerability of PF-05230907 in Intracerebral Hemorrhage

Last updated on April 19, 2019

FOR MORE INFORMATION
Study Location
Barnes Jewish Hospital
Saint Louis, Missouri, 63110 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Intracerebral Hemorrhage
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-79 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- ICH as documented by CT scan within 6.0 hours of symptom onset

- Baseline ICH volume > 5mL and

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Deep coma (Glasgow Coma Scale

- Modified Rankin Score > 3 prior to ICH onset

- Known history of schemic, vaso-occlusive or thrombotic events within 6 months prior to
screening

- Known prothrombotic disorders

- Known secondary ICH related to aneurysm, arteriovenous malformation, subarachnoid
hemorrhage, trauma, or other causes. CT angiography, MR, or other diagnostic studies
obtained as part of the standard of care may be used to assess eligibility.

- Known use of oral anticoagulant(s)

- Known use of low-molecular weight heparin or heparin

NCT02687191
Pfizer
Terminated
Safety and Tolerability of PF-05230907 in Intracerebral Hemorrhage

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now